ConjuChem Initiates Phase II Study of PC-DAC(TM):Exendin-4



    - First of Two Phase II Studies -

    MONTREAL, Feb. 20 /CNW/ - ConjuChem Biotechnologies Inc. (TSX:CJB) today
announced that dosing has been initiated in its Phase II clinical study for
the treatment of Type 2 diabetes using the Company's proprietary
PC-DAC(TM):Exendin-4 compound. The study is the first of two Phase II studies
that the Company plans to conduct concurrently.
    This Phase II trial, a randomized, double-blind, placebo-controlled,
multiple dose study, will evaluate the efficacy and safety of three months of
weekly injections of PC-DAC(TM):Exendin-4 in patients with Type 2 diabetes not
adequately controlled by metformin monotherapy. The trial will enroll 90
patients with 30 patients randomized to one of three parallel treatment
groups: a 1.5mg fixed weekly dose group; a group receiving a 1.5mg weekly dose
titrating to 2mg at the 5th week; and a placebo group.
    The dosing levels selected for the trial were a result of bridging
studies conducted in 2007 by ConjuChem with a new manufacturing process. The
manufacturing process improvements were successful in removing inactive
peptide constructs resulting in a more potent drug product thereby requiring
lower doses.
    A second Phase II trial is also planned which will be a randomized,
double-blind, placebo-controlled, multiple dose study, to evaluate the
efficacy and safety of three months treatment with PC-DAC(TM):Exendin-4 in
Type 2 diabetes patients not adequately controlled by metformin monotherapy.
The trial will enroll 90 patients with 30 patients randomized to one of three
parallel treatment groups: a 1.5mg fixed twice-weekly dose group; a group
receiving 1.5mg twice-weekly titrating to a 2mg weekly dose at the 5th week;
and a placebo group. This trial is designed to explore the efficacy and safety
profile of twice-weekly titration and maintenance dosing and is expected to
begin later in the first quarter.

    About PC-DAC(TM):Exendin-4

    PC-DAC(TM):Exendin-4 is a therapy being developed for Type II diabetes.
Exendin-4, like Glucagon-like peptide-1 (GLP-1), is an insulinotropic peptide
and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and
increases insulin secretion in a glucose-dependent manner. Exendin-4 may
stimulate (beta)-cell proliferation, restore (beta)-cell sensitivity to
glucose, delay gastric emptying, and increase peripheral sensitivity to
glucose. The clinical utility of Exendin-4 is somewhat limited by its
relatively short half-life in plasma. Developed with ConjuChem's proprietary
PC-DAC(TM) technology, PC-DAC(TM):Exendin-4 is a modified Exendin-4 analogue
that is covalently bound to recombinant human albumin (Recombumin(R), provided
by Novozymes Biopharma UK Limited). Data from Phase I/II clinical studies have
demonstrated that the preformed albumin-peptide conjugate has a much longer
half-life than the peptide alone. The product is a highly soluble liquid
formulation that is injectable in a small volume with a small gauge needle.

    About ConjuChem Biotechnologies

    ConjuChem, developer of next generation medicines from therapeutic
peptides, is creating long-acting compounds based on bioconjugation platform
technologies. When applied to peptides, the Company's DAC(TM) and PC-DAC(TM)
technologies enable the creation of new drugs with significantly enhanced
therapeutic properties as compared to the original peptide.
    Detailed descriptions of the Company can be viewed on the Company's
website www.conjuchem.com.

    Forward-Looking Statements

    Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause ConjuChem's actual results, performance or achievements
to be materially different from those expressed or implied by any of the
Company's statements. Actual events or results may differ materially. We
disclaim any intention, and assume no obligation, to update these
forward-looking statements.





For further information:

For further information: Lennie Ryer, CA, Vice President Finance & CFO,
ConjuChem Biotechnologies Inc., (514) 844-5558 ext 224, ryer@conjuchem.com;
James Smith, Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080,
jsmith@equicomgroup.com

Organization Profile

CONJUCHEM BIOTECHNOLOGIES INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890